Skip to main content
. Author manuscript; available in PMC: 2013 May 1.
Published in final edited form as: Clin Cancer Res. 2012 Mar 15;18(9):2668–2678. doi: 10.1158/1078-0432.CCR-12-0261

Table 1.

Patient and disease characteristics

Characteristic Patients (N = 15)
Median age, y (range) 65 (46 – 76)
ECOG performance status, n (%)
    0 7 (46.7)
    1 8 (53.3)
Race/Ethnicity, n (%)
    White, Hispanic 3 (20.0)
    White, non-Hispanic 12 (80.0)
Primary site, n (%)
    Ovarian 10 (66.7)
    Fallopian tube 3 (20.0)
    Peritoneal 2 (13.3)
FIGO stage, n (%)
    IIIC 15 (100.0)
Cell type, n (%)
    Serous 13 (86.7)
    Mixed epithelial 1 (6.7)
    Other 1 (6.7)
Tumor grade, n (%)
    2 1 (6.7)
    3 14 (93.3)
Primary site, n (%)
    Ovarian 10 (66.7)
    Fallopian tube 3 (20.0)
    Peritoneal 2 (13.3)
Residual disease, n (%)
    0 5 (33.3)
    <1cm 10 (66.7)
Neoadjuvant chemotherapy, n (%)
    Yes 3 (20.0)
    No 12 (80.0)

Abbreviation: ECOG, Eastern Cooperative Oncology Group

Abbreviation: FIGO, International Federation of Gynecology and Obstetrics